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Background: Alopecia Areata (AA) is a disease characterized by hair loss that is widely believed to be
autoimmune in origin. Thus treatment is generally aimed in this direction using immune inhibitors such
as steroids and PUVA.
Objective: To describe a variant of AA, Pseudo Alopecia Areata, caused by a particular cupola pin
holder (tic-tac) and to offer a non-pharmacological treatment option (NPT).
Methods: A prospective open label study in 37 Jewish religious patients (34 males, 3 females, mean
35 ^ 2 years), previously diagnosed and treated for scalp AA were randomly referred to one of the
three NPT intervention methods: small cupola held by two pins, large cupola held by one pin and
similar cupola held by a different pin.
Results: Three of the ten patients (33.3%) from the ﬁrst group developed secondary AA from the
additionalpin.Nochangeswereseeninthesecondgroup.Tenoftheseventeenpatients(58.8%)fromthe
third group achieved immediateimprovementsubsequenttoreplacing theoriginal pinwitha newoneon
a larger cupola.
Conclusions: Conservative pharmacological treatment failed to repair the lesions. The addition of a
secondpincausedanadditionallesion.Incontrast,replacingthecupolawithalargeroneandtheoriginal
pin-fastener with a different type, successfully reduced the lesions.
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INTRODUCTION
Alopecia Areata (AA) is a disease of unknown
etiology characterized by hair loss. It can affect men,
women or children (Madani and Shapiro, 2000).
Although other causes have been suggested, it is
widely believed that AA is an autoimmune disease
(Sahn, 1995; McElwee et al., 1999; Madani and Shapiro,
2000; Yano et al., 2002) because of the likely presence
of antimicrosomal antibody (Ab), antithyroglobulin
Ab, antigastric parietal cell Ab and adrenal cell Ab
(Paus et al., 1993; McDonagh and Messenger, 1994;
Schwartz and Janniger, 1997). There is no conclusive
diagnostic test for AA. Dermatologists occasionally
rely on clinical ﬁndings for diagnosis. Typically,
the initial lesion appears as a smooth bald patch.
Deﬁnitive diagnosis can be made by skin biopsy
showing a reduction in hair follicle anagen/telogen
phase. Treatment of AA consists of a range of
therapies, for which partial success has been claimed.
Most of the current modalities used are more effective
in the milder forms than in those with extensive hair
loss. The various therapies can be divided into several
groups:
1. Irritants, such as Dithranol and Phenol (Sherertz and
Sloan, 1988; Price, 1999);
2. Immune inhibitors, such as steroids and PUVA
(HealyandRogers,1993;WhitmontandCooper,2003);
3. Cyclosporin A (Moreno et al.,2 0 0 2 ) ;
4. Immune enhancers (Shapiro, 1993; van der Steen
and Happle, 1993) such asInosipleyand Thyomopentin
and
5. Minoxidil and others (Olsen et al., 1992; Epstein, 1993;
Micali et al., 1996; Sharquie and Al-Obaidi, 2002).
Treatment of the concomitant psychopathological
disorder has also been suggested (Garica-Hernandez
et al., 1999). Positive prognosis is based on the assertion
that AA sufferers are capable of re-growing hair even after
many years of hair loss. Spontaneous re-growth occurs in
10–30% of cases. In this article, we describe 37 patients
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port of entry for all our patients was the use of a metal clip
to hold a skull-cap in place. Skull-caps of various sizes
and shapes are widely used in many religions. We describe
a new method of treatment for this unique form of AA that
we refer to as Pseudo Alopecia Areata (PAA).
PATIENTS AND METHODS
Thirtyseven healthy white patients (34 males, 3 females)
aged 22–52 years (mean 35 ^ 6), formerly diagnosed
with scalp AA, were selected. Subjects were selected
according to their order of appearance. All patients resided
in the cities of Ashkelon and Rehovot, in Israel, between
the years 1997 and 2000. All were patients of the
dermatology departments of the two medical centers. The
only reason for them arriving at the dermatology clinic
was scalp AA.
The study had been approved by the Institutional
Review Board Committee and all subjects gave written
informed consent.
Complete clinical and laboratory examinations to
eliminate other possible causes for hair loss were
conducted. The diagnosis was conﬁrmed histologically,
according to established criteria of reduction in the
alogen/telogen phase of hair follicle. Damaged hair
follicles and inﬂammatory changes were also seen.
All patients wore a skull-cap which was reinforced to
the hair by a metal clip and all had local alopecia
characterized by a port of entry part of the bald lesion
(Fig. 1). We assumed this remark was caused through
recurrent daily trauma by the metal clip (Fig. 2). This port
of entry was used as a remark in order to distinguish
between AA and PAA. The treatment modalities used
were: in 32 patients (86.5%) intradermal steroids and in
5 patients (13.5%) oral steroids. All patients received
topical steroids. After 1 month, no improvement was
noticed as a result of the above treatments. Thus, three
non-pharmacological treatments were randomly intro-
duced (1:1:2 order) in order to reduce the cupola
movements and thus the pin trauma, as follows:
1. Two pins, small cupola (10 patients),
2. One pin, large cupola (10 patients) and
3. Different pin, same cupola (17 patients). The different
pin was not made of metal and had no sharp edges.
The results were tested for statistical signiﬁcance using
the Student’s t-test.
RESULTS
Thirty-seven patients (34 males, 3 females) aged 22–52
years (Mean 35 ^ 6) with scalp lesions formerly
diagnosed as AA were selected. All failed to recover
with topical and intradermal or oral steroid treatments.
Non-pharmacological approaches used were the replace-
ment of the original cupola and pin fastener with the
following options:
1. Two pins, small cupola (10 patients),
2. One pin, larger cupola (10 patients) and
3. Different pin, same cupola (17 patients).
The ﬁrst method of fastening a small cupola with two
pins, thereby attempting to reduce the cupola movements
and thus the pin trauma, failed, and caused a second PAA
at the location of the additional pin (Fig. 2) in three of the
ten patients (30%). No changes were observed in the
second group, where a larger cupola was held in place by
one pin. Ten of the seventeen patients from the third
group (58.8%), where the original cupola was held in
place by a different pin, showed immediate hair re-growth
ðP , 0:001Þ:
FIGURE 1 Dressing cupola enhanced by pin, developed AAvariant (PAA) characterized by a posterior lower port of entry (see arrow) where the pin
holder (tic-tac) was inserted and attached.
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AA is a disease characterized by hair loss that is often
emotionally devastating for patients. Although the cause of
AA is unknown, it is widely believed to be an autoimmune
disease (McDonagh and Messenger, 1994; Sahn, 1995;
SchwartzandJanniger,1997;McElweeetal.,1999;Madani
and Shapiro, 2000; Yano et al., 2002). Treatment of AA
consists ofvarioustherapies, through which limited success
has been achieved. The pharmacological treatment consists
of the use of irritants, immune inhibitors, Cyclosporin A,
immune enhancers and others (Stroud, 1987; Sherertz and
Sloan, 1988; Healy and Rogers, 1993; Paus et al.,1 9 9 3 ;
McDonaghandMessenger,1994;Price,1999;Morenoetal.,
2002; Tsai et al., 2002; Whitmont and Cooper, 2003).
Spontaneous hair re-growth occurs in 10–30% of cases.
We selected 37 religious patients with a variant of AA
that we describe as PAA. All lesions were characterized by
a small remark in the posterior-lower part of the lesion.
The remark was a result of the recurrent trauma caused by
placing and releasing the special pin (tic-tac), and by the
continuous trauma caused by the pin’s intermittent
movements throughout the day.
When the pharmacological treatments failed, we
introduced non-pharmacological treatments. The ﬁrst
group used the two pins/small cupola method. This
method failed in 67% of patients, and furthermore, 33.3%
of patients developed a second PAA scalp lesion. This
treatment’s failure reinforced our theory that the induction
of PAA in these patients was a result of the pin fastener’s
irritating qualities. When we changed the pin and used a
bigger cupola, facilitated hair re-growth was seen.
We conclude that in those patients with cupola dressing
and with AA, when the lesions are characterized by a port
of entry in the posterior-lower part, where the special pin
(tic-tac) is inserted, a non-pharmcological approach is
more effective.
Although religious women use the same pinholder
(tic-tac) to hold their head scarf in place, they are less
likely to develop PAA and a male predominance was
noted. The reason for this might be the lesser irritation
caused by the pinholder in women due to the different
location of the pinholders on the scarf (behind the ears)
and the greater amount of hair.
From the three methods used, a larger cupola, changing
the pin type and careful insertion and removal of the pin,
are all recommended.
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FIGURE 2 The inside part used to hold the cupola with two different
types of metal pin holders. Note the sharpness of the metal end.
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